Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. About Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. President, Director and Chief Medical Officer of MyMD. “The

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. This study included longitudinal data from the International CDKL5 Disorder Database on 143 children whose caregivers completed a baseline and follow-up questionnaire. Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. During the trial, patients with focal seizures (n=19) showed a median 25.2 We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

JANUARY 10, 2022

DUBLIN–(BUSINESS WIRE)–The “U.S. In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. List To Data Sources. List To Data Sources. Market Definition.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

SEPTEMBER 14, 2021

Comprehensive health-related outcome data from study participants, that is inclusive of highly diverse demographics and behavioral habits, further enables brands to deliver targeted formulations to specific customer segments. Step five: The OBX and Radicle Science validated product is sent to production.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Cannabis Law Report

AUGUST 17, 2021

DUBLIN–(BUSINESS WIRE)–The “Respiratory Health Management Technology Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. The Strategic Imperative. Research Scope.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. For more information, visit www.mymd.com. About FTSE Russell.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

JULY 9, 2021

The Index is designed to provide exposure to the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

SEPTEMBER 20, 2021

TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. Additional CB4 products from the Opticann suite of branded products will be launched in the upcoming weeks, including CB4 Derma skin cream and CB4 Clear face gel skincare products uniquely backed by product specific clinical trial data.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

JULY 29, 2021

Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Tweet this. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Develop and maintain the Core Data Sheet and lead global labeling team meetings. Key Responsibilities. to attain group goals.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 7, 2021

& ROME–(BUSINESS WIRE)– $APDN #COVIDDiagnostics — Applied DNA Sciences, Inc. Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated with the Applied DNA-Evvivax LinearDNA™ COVID-19 vaccine candidate against the B.1.1.7

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

NOVEMBER 9, 2021

–(BUSINESS WIRE)– $APDN #CARTcell — Applied DNA Sciences, Inc. We find LinearDNA to be an excellent platform for CAR T-cell therapy development.”. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

OCTOBER 29, 2021

–(BUSINESS WIRE)– #Alzheimers –India Globalization Capital, Inc. The primary endpoint of this Phase 1 trial was safety and tolerability. Based on this study and subject to FDA concurrence the cannabis-based investigational drug IGC-AD1 was generally safe and well-tolerated by the Alzheimer’s trial participants.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., 1 Data published by Research and Markets, March 2018. Dr. Chapman Bio. MyMD: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 6, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anebulo Pharmaceuticals, Inc. Scott Anderson.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

DECEMBER 21, 2021

Also in November, it reported positive data on its standout IND, CYB003. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JULY 6, 2021

We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.” Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

DECEMBER 17, 2021

DUBLIN–(BUSINESS WIRE)–The “22q11.2 deletion syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Drug chapter segment of the 22q11.2

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– $APDN #CARTcell — Applied DNA Sciences, Inc. – Demand for Therapeutic DNA Drives Inquiries for Bulk LinearDNA – STONY BROOK, N.Y.–(BUSINESS

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . About Clinton: Clinton is an undergraduate student studying business.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Advise executive members on new laws, existing laws, and legal rights and obligations that would impact functionality of the business.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

AUGUST 10, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About Oravax Medical.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. business for 6 years expanding services throughout the United States. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JANUARY 20, 2022

Business combination with Silver Spike Acquisition Corp. ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. health care services opportunity.

Therapy 52

Therapy Research and Development Business Access 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. June 30, 2021. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52